CD79A and influenza: DPIs have been successfully employed in experimental pulmonary vaccines for influenza and SARS-CoV-2, showing enhanced mucosal IgA and systemic T cell responses compared to traditional injections; though, DPIs are less commonly used for vaccines so far.